Antrafenine
This is an old revision of this page, as edited by DePiep (talk | contribs) at 14:53, 2 April 2016 (Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
{{Drugbox | Watchedfields = changed | verifiedrevid = 437136259 | IUPAC_name = 2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl 2-{[7-(trifluoromethyl)quinolin-4-yl]amino}benzoate | image = Antrafenine.svg | tradename = | pregnancy_category = | legal_status = Rx-only | routes_of_administration = Oral | bioavailability = | metabolism = Hepatic | elimination_half-life = | excretion = Renal | CAS_number_Ref = Y | CAS_number = 55300-30-6 | ATC_prefix = none | ATC_suffix = | PubChem = 68723 | DrugBank_Ref = Y | DrugBank = DB01419 | ChemSpiderID_Ref = Y | ChemSpiderID = 61973 | UNII_Ref = Y | UNII = 21FS93Y6OE | ChEMBL_Ref = Y | ChEMBL = 345524 | C=30 | H=26 | F=6 | N=4 | O=2 | molecular_weight = 588.543 g/mol | smiles = FC(F)(F)c5ccc1c(nccc1Nc2ccccc2C(=O)OCCN4CCN(c3cc(ccc3)C(F)(F)F)CC4)c5 | StdInChI_Ref = Y | StdInChI = 1S/C30H26F6N4O2/c31-29(32,33)20-4-3-5-22(18-20)40-14-12-39(13-15-40)16-17-42-28(41)24-6-1-2-7-25(24)38-26-10-11-37-27-19-21(30(34,35)36)8-9-23(26)27/h1-11,18-19H,12-17H2,(H,37,38) | StdInChIKey_Ref = Y | StdInChIKey = NWGGKKGAFZIVBJ-UHFFFAOYSA-N }}
Antrafenine (Stakane) is a phenylpiperazine derivative drug invented in 1979.[1] It acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen,[2] but is not widely used as it has largely been replaced by newer drugs.
See also
References
- ^ Manoury PM, Dumas AP, Najer H, Branceni D, Prouteau M, Lefevre-Borg FM. Synthesis and analgesic activities of some (4-substituted phenyl-1-piperazinyl)alkyl 2-aminobenzoates and 2-aminonicotinates. Journal of Medicinal Chemistry. 1979 May;22(5):554-9.
- ^ Leatham PA, Bird HA, Wright V, Seymour D, Gordon A. A double blind study of antrafenine, naproxen and placebo in osteoarthrosis. European Journal of Rheumatology and Inflammation. 1983;6(2):209-11.
pyrazolones / pyrazolidines | |
---|---|
salicylates | |
acetic acid derivatives and related substances | |
oxicams | |
propionic acid derivatives (profens) |
|
n-arylanthranilic acids (fenamates) | |
COX-2 inhibitors (coxibs) | |
other | |
NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |
Receptor (ligands) |
| ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Enzyme (inhibitors) |
| ||||||||||||||||||||||||||
Others | |||||||||||||||||||||||||||
Simple piperazines (no additional rings) | |
---|---|
Phenylpiperazines |
|
Benzylpiperazines | |
Diphenylalkylpiperazines (benzhydrylalkylpiperazines) |
|
Pyrimidinylpiperazines | |
Pyridinylpiperazines | |
Benzo(iso)thiazolylpiperazines | |
Tricyclics (piperazine attached via side chain) |
|
Others/Uncategorized |